BioNexus Gene Lab (BGLC) Assets Average (2019 - 2026)

BioNexus Gene Lab (BGLC) has 8 years of Assets Average data on file, last reported at $9.1 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average fell 8.14% year-over-year to $9.1 million; the trailing twelve-month figure through Mar 2026 stood at $9.1 million (down 8.14% YoY), and the FY2025 full-year result was $9.8 million, down 9.83% from the prior year.
• Assets Average climbed to $9.1 million in Q1 2026, from $8.4 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $11.4 million in Q4 2023 to a low of $8.0 million in Q2 2023.
• A 5-year average of $9.5 million and a median of $9.4 million in 2022 frame the typical range for Assets Average.
• Across the five-year window, Assets Average surged 38.64% in 2024 and retreated 23.01% in 2025, its largest moves.
• Tracing BGLC's Assets Average over 5 years: stood at $8.3 million in 2022, then soared by 38.26% to $11.4 million in 2023, then slipped by 6.28% to $10.7 million in 2024, then fell by 21.26% to $8.4 million in 2025, then advanced by 8.41% to $9.1 million in 2026.
• Business Quant data shows BGLC's Assets Average at $9.1 million in Q1 2026, $8.4 million in Q4 2025, and $8.5 million in Q3 2025.